Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677064 · ClinicalTrials.gov registry record
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
A clinical trial of Acute Leukemia and Newly Diagnosed, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 1,365
- Enrollment target
- 3
- Study locations
NCT02677064: Recruiting study of Acute Leukemia and Newly Diagnosed, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02677064 is a study of Acute Leukemia and Newly Diagnosed that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,365 participants, above the 426-participant average among 37 other Acute Leukemia trials with a reported enrollment target (220% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02677064, a study of Acute Leukemia and Newly Diagnosed, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 1,365 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.
Primary Outcome
determine whether an individual patient proceeded to HCT when he or she was considered eligible (based on NCCN guidelines.
Conditions Studied
Interventions
- OTHER assessments
Study Locations (3)
Connecticut
- Hartford Healthcare Cancer Institute @ Hartford Hospital - Hartford
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,365 participants |
| Start Date | 2016-02 |
| Est. Completion | 2027-02 |
What NCT02677064 shows while recruiting
NCT02677064 is an observational study that tracks outcomes without assigning an intervention. Its 1,365 participants enrollment target places it among the larger protocols in the corpus, above the 426-participant average among 37 other Acute Leukemia trials with a reported enrollment target (220% higher).
The record links to 3 conditions, with Acute Leukemia appearing as the primary indexed condition, and to 1 intervention - of which assessments is the first listed.
NCT02677064 reports a single indexed study location in Connecticut, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02677064 about?
NCT02677064 is a clinical study titled "Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia". The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explor...
What is the current status of trial NCT02677064?
This trial is currently recruiting. The enrollment target is 1,365 participants. The study started on 2016-02. Estimated completion is 2027-02.
What conditions does trial NCT02677064 study?
This clinical trial studies the following conditions: Acute Leukemia, Newly Diagnosed, Relapsed.
What interventions are being tested in trial NCT02677064?
The interventions under investigation include: assessments (OTHER).
Who is sponsoring clinical trial NCT02677064?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02677064 being conducted?
This trial has 3 study locations across Connecticut, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02677064's enrollment target sits among peer trials
1,365 4th of 37 higher than 34 of 37 other Acute Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia